Jasper Therapeutics shares are trading higher after Evercore ISI initiated coverage on the stock with an Outperform rating and $65 price target.
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics' stock price increased following Evercore ISI's initiation of coverage with an Outperform rating and a $65 price target.
April 03, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics' shares experienced a positive movement after receiving an Outperform rating and a $65 price target from Evercore ISI.
Analyst ratings, especially from reputable firms like Evercore ISI, can significantly influence investor sentiment and stock prices. The Outperform rating and ambitious $65 price target suggest a strong confidence in Jasper Therapeutics' future performance, likely leading to increased investor interest and a short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100